VYNE Therapeutics (VYNE) AI Stock Analysis

• Market Cap: $14.99M
• Dividend Yield: N/A
• Average Volume (3M): 280.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.13
• Revenue Growth: 43.03%
• EPS Growth: 81.75%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 16,664,892
• 10 Day Avg. Volume: 336,905
• 30 Day Avg. Volume: 280,682
• PEG Ratio: <0.01
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.29
• Enterprise Value/Market Cap: -1.51
• Enterprise Value/Revenue: -10.87
• Enterprise Value/Gross Profit: -37.45
• Enterprise Value/Ebitda: 0.15
• 1Y Price Target: $5.25
• Price Target Upside: 483.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 42 Neutral
• Price Target: $1.00 ▲(11.11%Upside)

VYNE Therapeutics' overall stock score is primarily influenced by its weak financial performance and valuation challenges. Persistent losses and cash flow issues significantly impact its financial score, while negative technical indicators reflect bearish market sentiment. The lack of profitability further exacerbates valuation concerns, leading to a low overall score.

Positive Factors

Clinical Developments

Repibresib gel showed rapid and meaningful clinical benefit with a favorable safety profile in a Phase Ib study.

Financial Stability

VYNE Therapeutics has $50.3 million in cash, which is expected to fund operations into the second half of 2026.

Product Advantages

Repibresib is administered once-daily and is not expected to have a black-box warning, offering advantages over the current standard of care.

Negative Factors

Non-clinical Observations

A clinical hold was placed on VYN202 Phase 1b trial due to recent observations of testicular toxicity in dogs from a non-clinical toxicology study.

Operational Interruptions

The company has suspended all screening, enrollment, and dosing in the VYN202 study and is working with the FDA to resolve the hold.

Regulatory Challenges

The FDA has placed a clinical hold on the Phase Ib study evaluating VYN202 due to testicular toxicity observed in dogs.

VYNE Therapeutics Business Overview & Revenue Model

Company Description

VYNE Therapeutics (VYNE) is a biopharmaceutical company focused on developing and commercializing innovative therapies for dermatology and other therapeutic areas. The company specializes in leveraging its proprietary molecule technology to create treatments that address unmet medical needs. VYNE's core products include topical treatments for acne and other dermatological conditions, with a strong emphasis on research and development to expand its pipeline.

How the Company Makes Money

VYNE Therapeutics generates revenue primarily through the commercialization of its dermatology products. The company earns money by selling its pharmaceutical treatments to healthcare providers, pharmacies, and distributors. Additionally, VYNE may engage in strategic partnerships or licensing agreements with other pharmaceutical companies to expand the market reach of its products, which can provide additional revenue streams through upfront payments, royalties, or milestone payments. The company's focus on research and development also positions it to potentially benefit from future product launches and innovations in its therapeutic areas.

VYNE Therapeutics Financial Statement Overview

Summary

VYNE Therapeutics is struggling financially with declining revenue, negative profitability margins, and ongoing cash flow issues. While the balance sheet shows low leverage, consistent losses and negative cash flow raise concerns about financial sustainability.

Income Statement

VYNE Therapeutics has shown a significant decline in revenue over recent years, with a steep drop from 2020 to 2024. The gross profit margin is positive, but the company is facing substantial operating losses as evidenced by negative EBIT and EBITDA margins. The net profit margin is also significantly negative, highlighting persistent unprofitability. These metrics indicate challenges in achieving revenue growth and controlling costs.

Balance Sheet

The company has maintained a healthy equity position with a low debt-to-equity ratio, suggesting limited leverage risk. However, there is a consistent decrease in stockholders' equity over the last few years. The equity ratio is relatively strong, indicating a stable asset base primarily funded by equity. Despite these strengths, profitability remains an issue.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash burn, which is a concern for sustainability. Free cash flow has been negative, with limited growth in free cash flow, suggesting cash management challenges. The company has relied on financing activities to supplement cash needs, which could pose future risks if access to capital markets becomes constrained.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
605.00K	501.00K	424.00K	477.00K	14.76M	20.99M
	Gross Profit
605.00K	501.00K	424.00K	477.00K	11.41M	19.60M
	EBIT
-45.45M	-43.64M	-29.26M	-34.30M	-68.03M	-113.47M
	EBITDA
-44.45M	-43.63M	-29.26M	-34.22M	-38.94M	-251.09M
	Net Income Common Stockholders
-42.20M	-39.83M	-28.45M	-33.95M	-73.33M	-255.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
50.27M	61.52M	93.25M	30.91M	42.25M	58.59M
	Total Assets
56.42M	66.91M	97.69M	40.76M	67.05M	93.74M
	Total Debt
63.00K	99.00K	214.00K	-349.00K	349.00K	34.78M
	Net Debt
-28.15M	-19.83M	-30.41M	-31.26M	-41.90M	-22.78M
	Total Liabilities
12.29M	14.82M	8.95M	9.56M	18.41M	56.25M
	Stockholders Equity
44.13M	52.09M	88.73M	31.20M	48.64M	37.49M
Cash Flow		Free Cash Flow
-37.57M	-34.09M	-25.34M	-29.20M	-56.37M	-137.19M
	Operating Cash Flow
-37.45M	-33.97M	-25.34M	-29.20M	-56.37M	-137.08M
	Investing Cash Flow
46.77M	23.36M	-57.35M	15.67M	1.03M	89.11M
	Financing Cash Flow
-224.00K	-141.00K	82.39M	1.65M	39.78M	61.81M

VYNE Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYNE, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.31, and below the 200-day MA of 2.14, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 28.39 is Positive, neither overbought nor oversold. The STOCH value of 8.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VYNE.

VYNE Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
DARE	47 Neutral	$26.82M	―	597.53%	―	88.13%	92.45%
PLUR	46 Neutral	$34.46M	―	-1205.58%	―	203.23%	13.57%
CLNN	46 Neutral	$36.83M	―	-1738.36%	―	-43.55%	69.81%
VYNE	42 Neutral	$14.99M	―	-66.15%	―	43.03%	81.75%
PYPD	41 Neutral	$34.75M	―	-853.05%	―	―	34.97%
NRSN	30 Underperform	$57.09M	―	-2880.11%	―	―	31.09%

VYNE Therapeutics Corporate Events

VYNE Therapeutics Sees Strong Shareholder Support for Growth

VYNE Therapeutics’ stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing shares available for issuance and adjusting share recycling policies. During the annual meeting, all five proposals, including director elections and executive compensation, were approved, indicating strong shareholder support and potential for strategic growth.